Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies  - Scorecard - MDSpire

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

Eugene M. & Christine E. Lynn Cancer Institute has treated its first patient with tarlatamab, marking an important milestone in the expansion of advanced cancer therapies available to patients in Palm Beach County and the surrounding region.

  • May 7, 2026

  • 3 min

Share

Clinical Scorecard: Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies

At a Glance

CategoryDetail
Condition
Key MechanismsTarlatamab is a T-cell engaging therapy that targets malignancies.
Target Population
Care Setting

Key Highlights

  • First patient treated with tarlatamab at Lynn Cancer Institute.
  • Represents expansion of advanced cancer therapies in Palm Beach County.
  • Requires coordinated support from a multidisciplinary team.

Guideline-Based Recommendations

Diagnosis

  • Identify appropriate patients with extensive-stage small cell lung cancer.

Management

  • Utilize a multidisciplinary team for the delivery of tarlatamab.

Monitoring & Follow-up

  • Implement close monitoring and timely intervention strategies.

Risks

  • Recognize the potential clinical complexity associated with tarlatamab therapy.

Patient & Prescribing Data

Patients with limited treatment options for extensive-stage small cell lung cancer.

Clinical Best Practices

  • Ensure coordinated care involving physicians, nurses, pharmacists, and lab technicians.

Related Resources & Content

Original Source(s)

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

  • May 7, 2026

Related Content

2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

  • July 2, 2026

  • 1 min
Virtual Staining and the Next Era of Pathology

How AI enables scalable biomarker analysis that preserves tissue samples, addressing some of the most persistent bottlenecks in clinical care and research

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min